AYTUHIGH SIGNALFINANCIAL10-K

AYTU executed a major $16.6 million equity raise in June 2025 while recording an $8.3 million impairment charge, amid dramatic revenue growth but deteriorating profitability and equity erosion.

The combination of a large equity raise, significant asset impairment, and substantial equity decline (-31.6%) suggests the company faced financial distress requiring immediate capital injection. The June 2025 timing indicates these events occurred after the fiscal year end, making this disclosure particularly material for investors assessing current financial position.

Comparing 2025-09-23 vs 2024-09-26View on EDGAR →
FINANCIAL ANALYSIS

AYTU showed explosive revenue growth (+278% to $27.6M) but this was overshadowed by deteriorating operational performance, with operating losses widening 49% to -$7.8M due to SG&A expenses nearly doubling to $34.8M. Despite raising $16.6 million in cash during June 2025, stockholders' equity declined sharply by 32% to $19.0M, indicating significant dilution from the emergency financing. The $8.3 million asset impairment combined with rising interest expense (+387%) and negative operating cash flow signals a company in financial distress despite top-line growth.

FINANCIAL STATEMENT CHANGES
Interest Expense
P&L
+386.7%
$536K$2.6M

Interest expense surged 386.7% — significant debt increase or rising rates materially impacting earnings.

Revenue
P&L
+277.5%
$7.3M$27.6M

Strong top-line growth of 277.5% — accelerating demand or successful expansion into new markets.

SG&A Expense
P&L
+84.3%
$18.9M$34.8M

SG&A up 84.3% — significant increase in sales or administrative costs, monitor impact on operating leverage.

Cash & Equivalents
Balance Sheet
+54.7%
$20.0M$31.0M

Cash position surged 54.7% — strong cash generation or capital raise providing significant financial cushion.

R&D Expense
P&L
-52.5%
$2.8M$1.3M

R&D spending cut 52.5% — could signal cost discipline or concerning reduction in innovation investment.

Operating Income
P&L
-49%
-$5.3M-$7.8M

Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.

Operating Cash Flow
Cash Flow
-39.6%
-$1.4M-$1.9M

Operating cash flow fell 39.6% — earnings quality concerns; investigate working capital changes and non-cash items.

Accounts Receivable
Balance Sheet
+31.9%
$23.6M$31.2M

Receivables surged 31.9% — revenue recognized but not yet collected; watch for collection issues or channel stuffing.

Stockholders Equity
Balance Sheet
-31.6%
$27.7M$19.0M

Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.

Capital Expenditure
Cash Flow
-30.7%
$329K$228K

Capex reduced 30.7% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

LANGUAGE CHANGES
NEW — 2025-09-23
PRIOR — 2024-09-26
ADDED
Each of these prefunded warrants is exercisable at any time for one share of the Company s common stock on a one-for-one basis under the terms of the agreements between the Company and the investors.
The number of warrants, excluding prefunded warrants, outstanding as of June 30, 2024, is comprised of 3,821,115 liability classified warrants and 18,114 equity classified warrants.
Relates to the June 2025 issuance of 8,233,332 prefunded warrants at a public offering price of $1.4999 to purchase 8,233,332 shares of the Company s common stock at an exercise price of $0.0001 per share (the June 2025 Prefunded Warrants ).
In June 2025, the Company recorded an impairment to its product technology rights intangible asset of $8.3 million.
Accordingly, $19.1 million of gross carrying amount and $10.8 million of related accumulated amortization have been removed from this table as of June 30, 2025.
+7 more — sign up free →
REMOVED
The warrants issued during fiscal 2024 were a result of 1,806,434 Tranche B Warrants being exercise to 1,806,434 Tranche B Pre-Funded Warrants.
Expense associated with the wind down of the Consumer Health Segment is related to the Consumer Health Segment.
Expense associated with the closure of the Grand Prairie, Texas manufacturing site is related to the Rx Segment.
The number of warrants outstanding as of June 30, 2023, is comprised of 6,068,763 liability classified warrants, 430,217 liability classified June 2023 Pre-Funded Warrants and 39,072 equity classified warrants.
Expense associated with severance and employee benefits and exit and disposal activities are included in restructuring costs in the consolidated statements of operations.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →